Deep learning has achieved great success in the fields of image analysis and computer vision, and may therefore be a useful approach in the field of lung adenocarcinoma. Five different methods were compared to classify the ground-glass opacities (GGOs) for the prediction of the pathological subtypes of high-grade lung adenocarcinomas, including classic machine learning, radiomics with selected features, radiomics + deep learning, and radiomics and deep learning separately. A total of 31 patients with high-grade patterns and 80 patients who lacked such patterns were analysed.
It was found that the methods combining radiomics with deep learning achieve the highest accuracy among all methods, with an overall accuracy of 0.888. This significantly outperformed classic machine learning, and radiomics and deep learning alone (P<0.001; see Figure) [1]. These results, based on a small image dataset, indicate that radiomics and deep learning need to be combined to effectively classify GGO. The exploration of tumour images may contribute to better treatment planning and personalised medicine.
Figure. Classification results of different methods [1]
Another possible new screening method is based on breath analysis by using volatile organic compounds (VOCs). There is a clear need for non-invasive diagnostic biomarkers which are able to identify patients at risk or with early stage cancer and VOCs patterns seem to be a potential tool aimed at early diagnosis and follow-up of these neoplasms. Canito et al. aimed to develop and validate a methodological approach to identify a VOCs breath pattern in order to discriminate between patients with lung cancer, malignant pleural mesothelioma, and healthy subjects [2]. The study population consisted of 28 lung cancer patients, 14 patients with pleural mesothelioma, 5 asbestos-exposed patients, and 20 healthy subjects.
The model was found to have good prediction ability. It resulted in good accuracy of 84% in lung cancer (sensitivity 86% and specificity 83%). Regarding malignant pleural mesothelioma, a negative predictive value of 82%, a positive predictive value of 91%, and a prediction ability of 93% were obtained. Despite the small study population and some technical limitations, these preliminary data support the VOCs analysis as a potentially useful tool in the earlier diagnosis of lung and pleural neoplasms. However, further investigation into breath analysis is warranted, and a prospective study evaluating VOCs in exhaled breath of patients with malignant pleural mesothelioma and asbestos-exposed subjects is currently ongoing.
- Wang X, et al. MA10.02. WCLC 2019.
- Catino A, et al. MA10.05 WCLC 2019.
Posted on
Previous Article
« Treatment escalation over induction therapy Next Article
Pembrolizumab + chemotherapy beneficial in advanced NSCLC, even without PD-L1 expression »
« Treatment escalation over induction therapy Next Article
Pembrolizumab + chemotherapy beneficial in advanced NSCLC, even without PD-L1 expression »
Table of Contents: WCLC 2019
Featured articles
Five-fold increase of OS at 5 years with nivolumab vs docetaxel
Screening, Detection, and Diagnosis
Non-Small-Cell Lung Cancer
Five-fold increase of OS at 5 years with nivolumab vs docetaxel
Promising phase 1 results of novel KRAS-inhibitor in NSCLC
Selpercatinib (LOXO-292) shows durable activity in RET fusion-positive lung cancer
Other Thoracic Malignancies
Immuno-Oncology
Nivolumab + ipilimumab safe first-line treatment for NSCLC patients with comorbidities
Targeted Therapy
Phase 3 Trial Updates
First-line pembrolizumab monotherapy offers durable OS benefit vs chemotherapy in NSCLC patients with high PD-L1 expression
Related Articles
June 25, 2019
Brain irradiation as treatment option
September 21, 2021
Baseline CD8+ T-cells predict NSCLC immunotherapy safety
September 10, 2021
Ensartinib bests crizotinib in ALK-positive non-small cell lung cancer
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com